Arlene Weintraub

Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.

Recent posts

Rhythm Drums Up $25M to Advance Diabetes and Obesity Drugs

Boston-based Rhythm Pharmaceuticals is announcing today it has raised $25 million in a Series B financing round, bringing the total amount of capital hauled in by the two-year-old company to $65... Read more »
Merck Sleep Drug Hits Trial Goals, Raising Hopes for New Blockbuster

At the annual meeting of the Associated Professional Sleep Societies in Boston today, drug giant Merck (NYSE: MRK) released promising data from two late-stage human trials of its experimental insomnia... Read more »
Bristol-Myers Wrangles Top Academics to Study Immunity in Cancer

On May 29, New York-based drug giant Bristol-Myers Squibb (NYSE: BMY) announced a major international cancer-research initiative—news that got a bit overshadowed by the biggest cancer conference of the... Read more »
FDA Rejects Ariad/Merck Sarcoma Pill, Wall Street Unfazed

When the FDA gave the thumbs-down last night to ridaforolimus (Taltorvic)—a drug being co-developed by Ariad Pharmaceuticals and Merck to treat metastatic soft-tissue sarcoma or bone sarcoma—investors barely flinched. Shares of Cambridge,... Read more »
Bayer Oncology Dubs ASCO “Turning Point” for Cancer Efforts

If one were to list the top cancer drugmakers of all time, it’s fair to say Bayer wouldn’t make the top 10. Despite the German drug giant’s leadership position across the... Read more »
NYC’s Radiator Labs Nabs MIT Clean Tech Prize, Vies for New US Crown

Marshall Cox moved into graduate housing at Columbia University a couple years back and immediately ran into a problem that plagues many New York City residents. His apartment was too hot.... Read more »
Merck Oncology Chief Heads to ASCO With High Hopes for New Drugs

At the annual conference of the American Society of Clinical Oncology (ASCO), starting tomorrow in Chicago, drug giant Merck will be presenting no less than 100 abstracts detailing its efforts to... Read more »
N-of-One Names CEO, Forms Pact With Foundation Medicine

Waltham, MA-based N-of-One announced today several milestones in its quest to provide tools that can help oncologists design personalized treatment regimens for their patients. The company, founded in 2008 by Harvard-trained... Read more »
Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial

[Updated 5/30/12 8:30 am. See below.] Today Woburn, MA-based Flexion Therapeutics announced that its treatment for osteoarthritis met its goal of significantly relieving joint pain in a mid-stage trial.... Read more »
Genentech, Roche Find New Balance Three Years Post-Merger

In late 2009, I wrote a feature story for BusinessWeek that was given the clever and rather blunt headline “Can Roche Leave Genentech Alone?” It was a pressing question at the... Read more »
The 2012 New York ASCO Checklist

On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical... Read more »
Halo Gathers $1.1M From Patient Groups for Muscular Dystrophy Drug

At first glance, the $1.1 million financing announced by Halo Therapeutics on Tuesday looked like your average case of a biotech startup scraping together enough money to get its early-stage compound... Read more »
Ra Pharma Pours $8.6M Into Discovery Tech and New Rare-Disease Drug

Today Ra Pharmaceuticals CEO Doug Treco will make a presentation at a conference in Las Vegas that will cap off the Cambridge, MA-based company’s weeklong unveiling. On May 16, Ra announced... Read more »
Undaunted by Wall Street “Penalty Box,” Keryx Focuses on Kidney Drug

On April 2, shares of New York-based Keryx Pharmaceuticals (NASDAQ: KERX) fell a stomach-churning 65 percent to $1.74 after the company announced that a late-stage trial of its colon cancer... Read more »
Xconomist of the Week: Tom Maniatis on Prize4Life and ALS Research

A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with amyotrophic... Read more »
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire Vet as CEO

Biotech firm Promedior announced today that it will be moving its headquarters from Malvern, PA, to Boston, and that it has hired a new CEO, Suzanne Bruhn,who was previously senior vice... Read more »
Lenddo Grabs $8M, Expands Microloan Model to Asia and Latin America

New York-based Lenddo, which uses social media to help middle-class folks in emerging countries secure loans, announced today that it has raised $8 million in a Series A funding round. Investors... Read more »
Five Questions for E&Y’s David DeMarco on the Future of Health IT

In March, global consulting firm Ernst & Young released an annual report for its life sciences clients called “The Third Place: Healthcare Everywhere.” It discusses a range of topics, from apps... Read more »
New Tech City: Has NYC Passed Boston in Mobile and Web Innovation?

On Wednesday, New York-based Center for an Urban Future, a policy think tank, released a report surveying the city’s digital startup scene, and its conclusion was rather dramatic: New York has... Read more »
NY’s Cancer Research Institute Looks to Boost Cancer Immunotherapy

When the Cancer Research Institute was founded in 1953 in New York, it set out to pursue an idea that was radical at the time—the notion that mobilizing the body’s innate... Read more »

Page 3 of 22 « previous page · next page »

Arlene Weintraub

Recent posts

Underwriters and Partners

Xconomy Events Across the Network

Connect with Xconomy

Xconomy’s Most Popular

Xconomy on Demand